Please login to the form below

Not currently logged in
Email:
Password:

David Colpman joins Forendo Pharma’s board

He becomes a non-executive director

David ColpmanForendo Pharma, a drug development company, has appointed David Colpman to its board of directors.

Colpman, who becomes the group’s non-executive director, brings with him a career of more than 25 years in pharma and biotech business development and strategy.

He said: “I see great opportunities for Forendo, and look forward to working with the experienced team in the company.”

His previous roles include head of global business development at Shire and business development and commercial positions at Glaxo Wellcome - now GlaxoSmithKline - and Novo Nordisk.

Risto Lammintausta, chief executive officer of Forendo Pharma, said: “We are delighted to welcome David with his broad experience in the industry that will be of significant benefit to Forendo.

“His insights and expertise will be very helpful as we continue to evaluate the commercial alternative of our programmes.”

29th March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics